1125 GMT - Novo Nordisk is a "screaming buy," AlphaValue analyst Abhishek Raval writes. The company has a lead in the obesity market, a solid pipeline, aggressive intent toward licensing deals, and a valuation lower than both Novartis and AstraZeneca, he says. Underwhelming late-stage results from obesity candidate CagriSema, Trump tariff uncertainty, and concerns around a guidance downgrade due to competitive pressures have all weighed on Novo's share price. Nonetheless, AlphaValue has already baked some caution into 2025 estimates and still expects Novo's bottom line to register a 16% compound annual growth rate, which would be the highest among European big pharma over 2024-2027. AlphaValue lowers its target price on the stock to 943 Danish kroner from 981 kroner and retains its buy rating. Shares fall 2.4% to 467.75 kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
April 02, 2025 07:25 ET (11:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.